NICE gives final nod to GSK's Revolade, Otsuka's Abilify and Bayer's Eylea
This article was originally published in Scrip
Executive Summary
Funding in England and Wales should soon be guaranteed for Otsuka's bipolar treatment Abilify (aripiprazole), Bayer's eye drug Eylea (aflibercept) and GlaxoSmithKline's Revolade (eltrombopag) for chronic immune (idiopathic) thrombocytopenic purpura. NICE, the health technology appraisal institute for England and Wales, has published final and binding guidance recommending the three drugs, which means that local authorities have to make funds available to cover them within 90 days.